Real-time Estimate
Cboe BZX
01:50:39 2024-06-14 pm EDT
|
5-day change
|
1st Jan Change
|
7.44
USD
|
-4.92%
|
|
-7.34%
|
-33.51%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
3,733
|
3,318
|
1,806
|
1,357
|
1,039
|
-
|
-
|
Enterprise Value (EV)
1 |
3,309
|
3,061
|
1,712
|
1,267
|
862.3
|
902.2
|
983.3
|
P/E ratio
|
-7.7
x
|
-8.04
x
|
-5.77
x
|
-3.95
x
|
-2.77
x
|
-2.71
x
|
-2.95
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
45.2
x
|
1,095
x
|
1,308
x
|
53.1
x
|
102
x
|
155
x
|
25.2
x
|
EV / Revenue
|
40
x
|
1,011
x
|
1,240
x
|
49.6
x
|
84.3
x
|
134
x
|
23.8
x
|
EV / EBITDA
|
-63.3
x
|
-8.55
x
|
-5.8
x
|
-3.45
x
|
-2.21
x
|
-2.31
x
|
-2.25
x
|
EV / FCF
|
-31.7
x
|
-39.3
x
|
-7.18
x
|
-4.16
x
|
-3.55
x
|
-2.87
x
|
-3.8
x
|
FCF Yield
|
-3.16%
|
-2.54%
|
-13.9%
|
-24%
|
-28.2%
|
-34.9%
|
-26.3%
|
Price to Book
|
4.9
x
|
3.7
x
|
1.76
x
|
1.79
x
|
1.45
x
|
-
|
-
|
Nbr of stocks (in thousands)
|
89,811
|
108,044
|
120,895
|
123,269
|
132,742
|
-
|
-
|
Reference price
2 |
41.56
|
30.71
|
14.94
|
11.01
|
7.825
|
7.825
|
7.825
|
Announcement Date
|
3/25/21
|
2/24/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
82.65
|
3.029
|
1.381
|
25.55
|
10.23
|
6.711
|
41.28
|
EBITDA
1 |
-52.25
|
-357.9
|
-295.1
|
-367.7
|
-390.3
|
-390.1
|
-437.9
|
EBIT
1 |
-55.8
|
-361.9
|
-299.3
|
-373
|
-400.2
|
-417.9
|
-413.6
|
Operating Margin
|
-67.51%
|
-11,946.58%
|
-21,670.89%
|
-1,460.11%
|
-3,912.06%
|
-6,226.42%
|
-1,001.89%
|
Earnings before Tax (EBT)
1 |
-52.41
|
-363.9
|
-290.5
|
-342
|
-375.6
|
-398.1
|
-399.6
|
Net income
1 |
-230.2
|
-363.9
|
-290.5
|
-342
|
-376.7
|
-404
|
-409.8
|
Net margin
|
-278.51%
|
-12,012.94%
|
-21,036.13%
|
-1,338.66%
|
-3,682.23%
|
-6,019.19%
|
-992.72%
|
EPS
2 |
-5.400
|
-3.820
|
-2.590
|
-2.790
|
-2.824
|
-2.883
|
-2.654
|
Free Cash Flow
1 |
-104.4
|
-77.88
|
-238.6
|
-304.4
|
-242.8
|
-314.6
|
-258.6
|
FCF margin
|
-126.33%
|
-2,571.05%
|
-17,273.86%
|
-1,191.74%
|
-2,373.56%
|
-4,687.79%
|
-626.45%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/25/21
|
2/24/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
0.567
|
0.419
|
0.365
|
0.344
|
0.253
|
0.226
|
0.119
|
25.2
|
-
|
10.01
|
0.0889
|
0.1
|
0.0889
|
0.05
|
0.05
|
EBITDA
1 |
-65.85
|
-
|
-
|
-
|
-
|
-99.98
|
-104.7
|
-72.21
|
-90.82
|
-88.97
|
-98
|
-96
|
-93
|
-98
|
-101
|
EBIT
1 |
-66.89
|
-62.72
|
-77.81
|
-85.89
|
-72.85
|
-101.2
|
-106
|
-73.58
|
-92.2
|
-90.36
|
-102.9
|
-102.8
|
-102.9
|
-103
|
-105.2
|
Operating Margin
|
-11,796.65%
|
-14,969.21%
|
-21,318.08%
|
-24,968.6%
|
-28,794.86%
|
-44,768.58%
|
-89,117.65%
|
-291.95%
|
-
|
-903%
|
-115,769.57%
|
-102,845.86%
|
-115,773.43%
|
-206,066.5%
|
-210,320%
|
Earnings before Tax (EBT)
1 |
-67.46
|
-62.05
|
-76.79
|
-84.17
|
-67.5
|
-94.24
|
-98.5
|
-65.73
|
-83.5
|
-81.39
|
-95.76
|
-96.85
|
-97.99
|
-98.38
|
-100.3
|
Net income
1 |
-67.46
|
-62.05
|
-76.79
|
-84.17
|
-67.5
|
-94.24
|
-98.5
|
-65.73
|
-83.5
|
-81.39
|
-92.19
|
-98.43
|
-93.65
|
-100.6
|
-102.7
|
Net margin
|
-11,897%
|
-14,808.11%
|
-21,037.81%
|
-24,468.6%
|
-26,681.03%
|
-41,698.67%
|
-82,777.31%
|
-260.83%
|
-
|
-813.3%
|
-103,707.11%
|
-98,430%
|
-105,355.36%
|
-201,284.5%
|
-205,420%
|
EPS
2 |
-0.6200
|
-0.5700
|
-0.7100
|
-0.7600
|
-0.5600
|
-0.7800
|
-0.8100
|
-0.5400
|
-0.6700
|
-0.6200
|
-0.7330
|
-0.7250
|
-0.7200
|
-0.7150
|
-0.7275
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/24/22
|
5/5/22
|
8/4/22
|
11/3/22
|
2/23/23
|
5/4/23
|
8/8/23
|
11/2/23
|
2/22/24
|
5/2/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
423
|
257
|
94.1
|
90.3
|
176
|
137
|
55.4
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-104
|
-77.9
|
-239
|
-304
|
-243
|
-315
|
-259
|
ROE (net income / shareholders' equity)
|
-79%
|
-43.8%
|
-31.4%
|
-40.2%
|
-59.4%
|
-51%
|
-45.9%
|
ROA (Net income/ Total Assets)
|
-38.6%
|
-40.2%
|
-27.6%
|
-35.2%
|
-42.3%
|
-40%
|
-35.9%
|
Assets
1 |
596.4
|
904.1
|
1,054
|
971.9
|
890.5
|
1,010
|
1,142
|
Book Value Per Share
2 |
8.480
|
8.300
|
8.470
|
6.130
|
5.410
|
-
|
-
|
Cash Flow per Share
2 |
-
|
-0.7800
|
-2.040
|
-2.450
|
-2.280
|
-1.920
|
-
|
Capex
1 |
1.93
|
3.47
|
9.06
|
4.13
|
5.35
|
5.14
|
5.17
|
Capex / Sales
|
2.34%
|
114.59%
|
656.19%
|
16.15%
|
52.29%
|
76.61%
|
12.53%
|
Announcement Date
|
3/25/21
|
2/24/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Last Close Price
7.825
USD Average target price
22.05
USD Spread / Average Target +181.85% Consensus |
1st Jan change
|
Capi.
|
---|
| -33.51% | 1.04B | | +39.99% | 55.66B | | -8.15% | 38.98B | | +35.79% | 38.8B | | -8.98% | 27.32B | | +11.00% | 26.29B | | -16.30% | 20.25B | | +30.45% | 12.76B | | +27.23% | 12.18B | | -1.15% | 12.12B |
Other Biotechnology & Medical Research
|